By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Bio-Rad receives pre-market approval for HIV test from FDA
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Bio-Rad receives pre-market approval for HIV test from FDA
BusinessDiagnostics

Bio-Rad receives pre-market approval for HIV test from FDA

HerinaAyot
HerinaAyot
Share
3 Min Read
SHARE

Bio-Rad Laboratories (NYSE:BIO) announced Monday it received FDA premarket approval for its fourth generation human immunodeficiency virus (HIV) diagnostic test.

Bio-Rad Laboratories (NYSE:BIO) announced Monday it received FDA premarket approval for its fourth generation human immunodeficiency virus (HIV) diagnostic test.

Because the testing kit was deemed a Class III medical device, it was required to undergo premarket approval – the FDA’s most stringent regulatory measure – to obtain marketing clearance, as not enough information exists about these types of devices to ensure safety and efficacy in other ways.

According to the FDA, a Class III device is one that supports or sustains human life, is of substantial importance in preventing impairment of human health, or which presents a potential and unreasonable risk of illness or injury.

More Read

icd10 survey results - his
ICD-10 Readiness Survey Results
Medication Sticker Shock
Telestroke Initiative Website Launched
Health Insurance Exchange for Employers: Interview with ConnectedHealth [TRANSCRIPT]
More Pharmaceutical Industry Consolidation: Thinning Out the Middle

Examples of Class III devices which currently require a premarket notification include implantable pacemaker, pulse generators, and HIV diagnostic tests, among other products.

Bio-Rad’s HIV diagnostic, GS HIV Combo Ag/Ab EIA (enzyme immunoassay), detects two types of HIV proteins: antigens, which are part of the HIV virus, and antibodies, which the body releases to fight the HIV infection.
The test’s ability to detect two types of HIV proteins allows for earlier detection of the virus.

Over one million Americans are living with HIV, and one in five of them are unaware of their infection. Untreated, a patient suffering from HIV will eventually develop acquired immunodeficiency syndrome (AIDS), and, without anti-retroviral treatment, a person infected with the AIDS virus typically dies within one year.

“Detecting HIV antigens and HIV antibodies in the same test provides clinicians with the ability to detect the virus at an earlier stage,” said Vice President and Group Manager, Clinical Diagnostics, John Goetz.

“This results in faster diagnosis of HIV-infected individuals so they are able to get the treatment they need more quickly.”

Clinical studies for the diagnostic test were performed at five major institutions in the U.S. The large sample population included adults and pediatric patients, in both low and high risk populations.

Based in Hercules, California, Bio-Rad said the GS HIV Combo Ag/Ab EIA can be used with its EVOLIS system, a self-contained automated microplate processor, or with manual testing systems.–Olivia D’Orazio

 

TAGGED:Bio-RaddiagnosticsFDAHIV diagnostic test
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

uv protection in winter
Winter Sun Safety: Why UV Protection Matters Year-Round
Health
October 29, 2025
Nurse Scheduling Software
Evaluating 7 Best Nurse Scheduling Software
Nursing Technology
October 28, 2025
contamination
Batch Failures And The Hidden Costs Of Contamination
Health Infographics
October 21, 2025
Medication Management For Seniors
Simplifying Medication Management For Seniors
Infographics Senior Care
October 21, 2025

You Might also Like

Carestream Logo
DiagnosticsSpecialties

Diagnostic Reading #30: Five Must Read Articles From the Past Week

June 10, 2015

Healthcare Consumerism

June 28, 2011

HCA IPO – $3.8 Billion!

March 11, 2011

Healthcare Associated Infections: What is the Message, and What Can We Do About Them?

July 9, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?